Usage of TCR150-transgenic effector-memory-like PBLs to target disseminated tumor cells in vivo. (A) After THP-1_luc inoculation (1 × 10⁶ cells/mouse), transfer of 4 × 10⁵ CD8-enriched PBL_EMs was performed on days 1-3 using TCR150-transgenic CD8_EM cells. In addition, either IL-2 (36 μg/mouse/d) or IL-15 (10 μg/mouse/d) IP cytokine treatment was initiated on day 1 after tumor injection and given for 10 days. Shown is the measurement of the total flux (photons/s) as means (with SEM; n = 6 except for IL-2–treated groups n = 3) until the time point of the first dead mouse. (B) Survival of mice shown in panel C. Statistical calculation using the Mantel-Cox test indicated a significantly prolonged survival when mice received TCR150-transgenic CD8_EM (mean CD8_EM-TCRT58, 37.2 days, see supplemental Figure 4; mean CD8_EM-TCR150, 62 days; *P < .03). Addition of cytokine intraperitoneally with 3 injections of TCR150-CD8_EM showed a significant impact of IL-15 (70 days) compared with no cytokine (60 days; P = .01) or IL-2 administration (56 days; P = .003). (C) Representative examples of serial images of mice described in panels A and B.